Findings showed secukinumab demonstrated statistically significant and clinically meaningful sustained remission at week 52 vs placebo. Topline data were announced from a phase 3 trial evaluating ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

1 Republic of Turkey Ministry of Health University of Health Sciences Izmir Bozyaka Education and Research Hospital, Rheumatology, Izmir, Turkey 2 Republic of Turkey Ministry of Health Izmir Katip ...

Background Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are often overlapping inflammatory diseases that occur in people older than 50 years. Both diseases can affect the quality of ...

Introduction Chronic pain conditions are a leading cause of disease and disability. They are associated with symptoms such as fatigue, sleep and mood disturbances. Minimal evidence is available to ...